Methylene blue dye versus combined dye-radioactive tracer technique for sentinel lymph node localisation in early breast cancer

Varghese, Philip; Mostafa, A.; Abdel-Rahman, A.T.; Akberali, Samira; Gattuso, J.; Canizales, A.; Wells, Clive; Carpenter, R

doi:10.1016/j.ejso.2006.09.026

Cited by 54 publications

(40 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The meta-analysis established that the FNR is variable (0-29.4% but averaging 7.3% overall) and is affected by the SLNB method used; 10.9% and 8.8%, respectively for vital blue dyes and radiocolloid used as single agents, and 7.0% when a combined mapping procedure is used 64 . Subsequent studies which addressed both issues of FNR and anaphylaxis are recorded in table 2 10,38,43,44,51,65 . The FNRs of these "later" studies are consistent with the meta-analysis findings, but the precise contribution of Patent Blue V, Isosulfan Blue or Methylene blue in the studies cannot be accurately quantified.…”

Section: Level Of Anaphylactic Riskmentioning

confidence: 99%

“…The capacity of Methylene blue to function as a mapping agent needs to be tested in large trials, but evidence from small studies suggests that Methylene blue is equivalent to the patent blue dyes, e.g. one study demonstrate an identification rate of 98.7% in 329 early breast cancer patients 65 . Other studies have shown similar identification rates [73][74][75] .…”

Section: Avoidance Of Risk By Using Methylene Blue or Corticosteroid mentioning

confidence: 99%

See 1 more Smart Citation

Sentinel lymph node biopsy in early breast cancer surgery – Working with the risks of vital blue dye to reap the benefits

White

Harvey

Griffith

et al. 2011

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

Section: Level Of Anaphylactic Riskmentioning

confidence: 99%

Section: Avoidance Of Risk By Using Methylene Blue or Corticosteroid mentioning

confidence: 99%

Sentinel lymph node biopsy in early breast cancer surgery – Working with the risks of vital blue dye to reap the benefits

White

Harvey

Griffith

et al. 2011

European Journal of Surgical Oncology (EJSO)

View full text Add to dashboard Cite

“…Although the combined technique offers more rapid identification of SLN, the methylene blue dye technique alone can be used efficiently in centers which do not own nuclear medicine facilities [12].…”

Section: Discussionmentioning

confidence: 99%

Accuracy of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients; Single Center Experience

Elnahas¹,

Hamdy²,

Wahab³

et al. 2018

View full text Add to dashboard Cite

Purpose: Most important factor affecting prognosis of breast cancer is axillary nodal involvement. Several studies evaluated the accuracy of Sentinel lymph node biopsy in breast cancer patients post neoadjuvant chemotherapy. In this study, we will examine accuracy and feasibility of using Sentinel lymph node biopsy in predicting axillary lymph node status in breast cancer patients after neoadjuvant chemotherapy. Methods: 45 female patients with resectable, nonmetastatic breast carcinoma cases who received neoadjuvant chemotherapy were enrolled in this study according to the routine Mansoura Oncology Center-guidelines of management of breast cancer. Methylene blue dye used for detection of Sentinel lymph node. Results: Successful Sentinel lymph node detection was 82.2%. Skin involvement (T4 disease) were linked to a low identification (P = 0.005). False negative rate equals 11/27 = (40.7%).With advancement of the stage of the tumor, the incidence of false negative results increases significantly (p = 0.012) with 95% confidence interval; 1.2 -5.4. Conclusion: Sentinel lymph node should be adopted to be the standard method for axillary staging with T1-3 tumors after receiving neoadjuvant chemotherapy, in T4 patients, it is associated with low detection rate & high false negative rate making it doubtful technique for axillary staging.

show abstract

“…33 By this research, the usage of methylene blue dye was effective in identifying the sentinel node in 86.7% of cases and prior researches with identification rates of sentinel node identification using the methylene blue dye ranging from 83% to 93%. 12,22,34 The remaining patients who did not have dye in the SLN had involvement of these nodes with malignancy and this malignancy also impacted the non-sentinel axillary nodes. When identified successfully, sentinel lymph node biopsy accurately predicts the status of axillary node in 92.3% (12 of 13) and the false negative results in 12.5% (1 of 8).…”

Section: Discussionmentioning

confidence: 99%

Use of methylene blue for the detection of sentinel lymph node in breast cancer: a systematic review and meta-analysis

2017

View full text Add to dashboard Cite

Sentinel lymph node biopsy is the widely acceptable method for the examination of the breast cancer in the patients. This biopsy is considered as the best method for identifying the axillary involvement. Various dyes are used in this biopsy to find the sentinel lymph node. However, methylene blue dye (MBD) is considered to have a low risk of anaphylaxis, be cost effective and widely available.A systematic review and meta-analysis is performed on the utilisation of the methylene blue dye in the sentinel lymph node biopsy in the examination of breast cancer.Eight studies were appropriate for the inclusion criteria that were analysed systematically wherein meta- analysis is performed on studies which had ample data that comparatively analysed the efficiency of methylene blue. However, only two studies were selected for meta- analysis based on the availability of data.Systematic review reveals that methylene blue dye can be used as the best alternative when compared to other dyes in the detection of sentinel lymph node in the patients with breast cancer. However, the meta-analysis of two studies revealed no statistical significance defining the efficacy of methylene blue for sentinel lymph node detection.

show abstract

Methylene blue dye versus combined dye-radioactive tracer technique for sentinel lymph node localisation in early breast cancer

Cited by 54 publications

References 42 publications

Sentinel lymph node biopsy in early breast cancer surgery – Working with the risks of vital blue dye to reap the benefits

Sentinel lymph node biopsy in early breast cancer surgery – Working with the risks of vital blue dye to reap the benefits

Accuracy of Sentinel Lymph Node Biopsy after Neoadjuvant Chemotherapy in Breast Cancer Patients; Single Center Experience

Use of methylene blue for the detection of sentinel lymph node in breast cancer: a systematic review and meta-analysis

Contact Info

Product

Resources

About